Condition-Specific Health
Polyrizon's NASARIX™ Nasal Barrier Advances Human Residency Study
The characterization study aims to quantify how long the biopolymer barrier persists in the nasal cavity — a critical c…
Condition-Specific Health 100 stories
Condition-Specific Health
CAR-T Cell Therapy LB2501 Shows Early Clinical Signal in B-Cell Lymphoma
The dual-targeting CD19/CD20 mechanism marks a potential first-in-class approach, though the asset sits outside convent…
Condition-Specific Health
Anti-TL1A Therapy SPY002 Hits Primary Endpoint in UC Induction Trial
Gut-inflammation targeting moves further into clinical validation — with implications for next-gen functional ingredien…
Condition-Specific Health
Pasithea Therapeutics to Exhibit at 2026 NF Conference
The appearance marks a cross-sector moment as biotech pipelines intersect with functional and nutraceutical research in…
Condition-Specific Health
Lexeo LX2006 Gene Therapy Trial Targets Cardiac Endpoint in Friedreich Ataxia
The open-label study design and 6-month topline readout signal an accelerated path toward regulatory submission for the…
Condition-Specific Health
Context Therapeutics Reports 29% Response Rate in PROC Phase 1 Trial
Interim RECIST v1.1 data from Context Therapeutics positions CTIM-76 as a clinical-stage candidate in a heavily pre-tre…
Condition-Specific Health
ENA Respiratory Wins USPTO Patents for TLR2 Innate Immune Modulators
The allowances cover both composition-of-matter and method-of-use claims, strengthening IP position in the emerging inn…
Condition-Specific Health
AI Radiology Model Debuts at HLTH Europe 2026
The Saudi hospital's presentation signals growing crossover between precision diagnostics and functional health monitor…
Condition-Specific Health
MHRA Clears Needle-Free Epinephrine Device for Pediatric Anaphylaxis
The MHRA approval expands emergency allergy management options for a pediatric population where needle-based delivery h…
Condition-Specific Health
Enterome's OncoMimics™ EO2463 Drives CD8 T Cell Response in Phase 1/2 Lymphoma Study
Microbiome-mimicry immunotherapy edges toward clinical validation — with implications for how gut-derived peptides may …
Condition-Specific Health
Barzolvolimab Phase 2 Data Show Durable CSU Remission Off-Treatment
Celldex's anti-KIT monoclonal antibody moves the goalposts from symptom control to potential disease modification — a s…
Condition-Specific Health
Lorundrostat Linked to Heart Failure Biomarker Reductions in Proteomic Analysis
Late-breaking findings presented at the Endocrine Society Annual Meeting add cardiovascular biomarker evidence to the a…